Edwards Lifesciences Corporation
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.07B | $5.44B | $5.01B | $4.46B | $5.23B | $4.39B | $4.35B | $3.72B |
| Cost of Revenue | $1.33B | $1.12B | $978.4M | $723.7M | $1.25B | $1.08B | $1.11B | $939.4M |
| Gross Profit | $4.73B | $4.32B | $4.03B | $3.74B | $3.98B | $3.31B | $3.23B | $2.78B |
| Gross Margin | 78.0% | 79.5% | 80.5% | 83.8% | 76.1% | 75.4% | 74.4% | 74.8% |
| Operating Expenses | ||||||||
| Research & Development | $1.08B | $1.05B | $962.9M | $843.6M | $903.1M | $760.7M | $752.7M | $622.2M |
| SG&A Expense | $2.09B | $1.79B | $1.58B | $1.36B | $1.49B | $1.23B | $1.24B | $1.09B |
| Operating Income | $1.26B | $1.38B | $1.31B | $1.50B | $1.69B | $897.6M | $1.15B | $748.2M |
| Operating Margin | 20.8% | 25.3% | 26.1% | 33.6% | 32.3% | 20.5% | 26.4% | 20.1% |
| Interest Expense | — | — | $17.6M | $19.2M | $18.4M | $15.8M | $20.7M | $29.9M |
| Pretax Income | $1.27B | $1.55B | $1.37B | $1.52B | $1.70B | $916.7M | $1.17B | $761.4M |
| Income Tax Expense | $216.9M | $152.1M | $152.4M | $195.5M | $198.9M | $93.3M | $119.6M | $39.2M |
| Net Income | $1.07B | $4.17B | $1.40B | $1.52B | $1.50B | $823.4M | $1.05B | $722.2M |
| Net Margin | 17.7% | 76.7% | 28.0% | 34.1% | 28.7% | 18.8% | 24.1% | 19.4% |
| EPS (Basic) | $1.84 | $6.98 | $2.31 | $2.46 | $2.41 | $1.32 | $1.68 | $1.15 |
| EPS (Diluted) | $1.83 | $6.97 | $2.30 | $2.44 | $2.38 | $1.30 | $1.64 | $1.13 |
| Shares Outstanding (Basic) | 584.8M | 597.7M | 606.7M | 619.0M | 623.3M | 622.6M | 624.8M | 627.6M |
| Shares Outstanding (Diluted) | 585.8M | 599.3M | 609.4M | 624.2M | 631.2M | 631.9M | 636.7M | 640.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |